Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies

Rocha, Juliana Mendes; Reis, José Augusto Silva; Bouso, José Carlos; Hallak, Jaime Eduardo Cecílio; Santos, Rafael G. dos

doi:10.1007/s00406-023-01590-1

Cited by 7 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, various derivatives of Yuanzhi-1 have demonstrated antidepressant-like actions in animal behavioral models compared to those of the standard antidepressant duloxetine[ 94 ]. Ibogaine, a hallucinogenic alkaloid found in Tabernanthe iboga , is one example of how it has been empirically utilized to treat depression.…”

Section: Tcm Herbal Antidepressants: the Molecular Mechanism Of Their...mentioning

confidence: 99%

Exploring the transformative impact of traditional Chinese medicine on depression: Insights from animal models

Yang,

Chen,

Xie

2024

World J Psychiatry

View full text Add to dashboard Cite

Depression, a prevalent and complex mental health condition, presents a significant global health burden. Depression is one of the most frequent mental disorders; deaths from it account for 14.3% of people worldwide. In recent years, the integration of complementary and alternative medicine, including traditional Chinese medicine (TCM), has gained attention as a potential avenue for addressing depression. This comprehensive review critically assesses the efficacy of TCM interventions in alleviating depressive symptoms. An in-depth look at different research studies, clinical trials, and meta-analyses is used in this review to look into how TCM practices like herbal formulations, acupuncture, and mind-body practices work. The review looks at the quality of the evidence, the rigor of the methods, and any possible flaws in the current studies. This gives us an idea of where TCM stands right now in terms of treating depression. This comprehensive review aims to assess the efficacy of TCM interventions in alleviating depressive symptoms. In order to learn more about their possible healing effects, the study also looks into how different types of TCM work, such as herbal formulas, acupuncture, and mind-body practices.

show abstract

Section: Tcm Herbal Antidepressants: the Molecular Mechanism Of Their...mentioning

confidence: 99%

Exploring the transformative impact of traditional Chinese medicine on depression: Insights from animal models

Yang,

Chen,

Xie

2024

World J Psychiatry

View full text Add to dashboard Cite

show abstract

“…143 Other serotonergic psychedelics have cardiovascular risks, including QTc prolongation and possible valvular disease, warranting adequate screening and monitoring of participants with OUD, whose QTc interval may be prolonged at baseline, and who may have underlying cardiac disorders as a consequence of intravenous drug use. 147,148 The concurrent use of methadone, which has relevant cardiac effects, and a psychedelic like ibogaine (also with well documented cardiac effects) may warrant additional safety monitoring.…”

Section: Other Adverse Effectsmentioning

confidence: 99%

From Taboo to Treatment: The Emergence of Psychedelics in the Management of Pain and Opioid Use Disorder

Weleff,

Nunes,

Costa

et al. 2023

Preprint

View full text Add to dashboard Cite

The rise of psychedelics in contemporary medicine has sparked interest in their potential therapeutic applications. While traditionally associated with countercultural movements and recreational use, recent research has shed light on the potential benefits of psychedelics in various mental health conditions. In this review, we explore the emerging role of psychedelics in the management of chronic pain and opioid use disorder (OUD), two critical areas in need of innovative treatment options. Pain control remains a significant clinical challenge, particularly for individuals with OUD and those who receive long-term opioid therapy (LTOT) who develop marked tolerance to opioid-induced analgesia. Despite the magnitude of this problem, there is a scarcity of controlled studies investigating pain management alternatives for these populations. Drawing from preclinical and human evidence, we highlight the potential of psychedelics to act on shared neurobiological substrates of chronic pain and opioid use disorder, potentially reversing pain- and opioid-induced neuroadaptations, such as central sensitization. We elaborate on the multifaceted dimensions of the pain experience (sensory, affective, and cognitive) and their intersections that overlap with opioid-related phenomena (opioid craving and withdrawal), hypothesizing how these processes can be modulated by psychedelics. After summarizing the available clinical research, we propose mechanistic insights and methodological considerations for the design of future translational studies and clinical trials, building on a shared clinical and neurobiological understanding of chronic pain and OUD. Our intention is to provide timely perspectives that accelerate the development and exploration of novel therapeutics for chronic pain and OUD amidst the escalating opioid crisis.

show abstract

“…It is noteworthy that the majority of these cases occurred within uncontrolled settings, under unknown conditions of cardiovascular monitoring and medical supervision, and frequently involved the administration of high or indeterminate doses of ibogaine. Within this frame of reference, Rocha and colleagues conducted a systematic review to assess the utilization of ibogaine in clinical contexts and to analyze the settings [34]. In this review, six articles were included with an additional three studies in the development phase (as documented on ClinicalTrials.gov (accessed on 10 December 2020)).…”

Section: Ibogainementioning

confidence: 99%

“…However, through a qualitative analysis, it was possible to conclude that it is necessary to use ibogaine in a setting that offers safety to the participant, with cardiac monitoring and medical and psychiatric evaluation throughout the process, in addition to having trained professionals to deal with any side effects. In the article, the authors recommend the systematic recording of the setting in which ibogaine was applied so that it is possible to compare and develop protocols that guarantee safety [34].…”

Section: Ibogainementioning

confidence: 99%

See 1 more Smart Citation

Guidelines for Establishing Safety in Ayahuasca and Ibogaine Administration in Clinical Settings

Rocha,

Reis,

Rossi

et al. 2023

Psychoactives

Self Cite

View full text Add to dashboard Cite

As the research field with psychedelic substances grows, it is expected to encompass a more extensive cohort of individuals presenting a spectrum of medical conditions, comorbidities, and unique physiological traits, thereby increasing the likelihood of potential adverse events. Furthermore, it is worth noting that there is a scarcity of the specialized literature regarding procedures to ensure the safe management of clinical trials involving psychedelics. Acknowledging this, our research team designed a series of protocols to standardize the care and management of adverse scenarios, ensuring the safety and well-being of research volunteers included in clinical trials conducted by the LEAPS (Laboratory for Studies with Hallucinogens and Psychedelics in Mental Health, linked to the University of São Paulo). These guidelines have been meticulously crafted based on the established guideline philosophy of Hospital das Clínicas de Ribeirão Preto (the university hospital of Universidade de São Paulo), consultation with specialists in the field, and a thorough review of the existing literature. The process resulted in protocols that have been tailored to specifically address the unique requirements and particularities of clinical research with psychedelic substances (in this case, ayahuasca and ibogaine). As a result, these guidelines aim to cover a range of potential issues, encompassing both psychiatric manifestations (e.g., panic attacks, suicidal behavior, and psychotic episodes) and clinical manifestations (e.g., hypertensive crisis and hypoglycemia).

show abstract

Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies

Cited by 7 publications

References 39 publications

Exploring the transformative impact of traditional Chinese medicine on depression: Insights from animal models

Exploring the transformative impact of traditional Chinese medicine on depression: Insights from animal models

From Taboo to Treatment: The Emergence of Psychedelics in the Management of Pain and Opioid Use Disorder

Guidelines for Establishing Safety in Ayahuasca and Ibogaine Administration in Clinical Settings

Contact Info

Product

Resources

About